

Health and wellness initiatives - Lunch and Learn

***'COVID-19: latest developments in the search for effective COVID-19 vaccines and immune-based therapies'***


**Professor Stuart Berzins**

Professor of Immunology in the School of Science, Psychology and Sport

11 February 2021

# What is COVID-19?



- A virus is a package of parasitic genetic material
- This coronavirus is called SARS-Cov-2
- SARS-Cov-2 causes COVID-19.



An electron-microscope image of the COVID-19 virus. CSIRO



# How does it infect you?

*Spike proteins on the virus bind to ACE-2 proteins on our cells*





# Immune system is usually effective against COVID-19

- *T cells kill infected cells*
- 
- *Antibodies block virus infection*




# It takes time to build an immune army.....




**Ideally, this immune army would be ready before infection.**

**This is the aim of the vaccination program.**

# Vaccines induce the same protective immune response



## Vaccine



# Vaccines likely to be used in Australia's rollout

- **Pfizer/BioNTech) (10M doses (plus 10M)**
  - mRNA; 2 doses; reliant on overseas supply
  - Works well in young and old
  - Prevents severe disease
  - ~95% efficacy compared to placebo
  - Difficult to store (requires ultra cold refrigeration)
- **Astra-Zeneca (Oxford) (53M doses)**
  - adenovirus; 2 doses; can be made in Aust (CSL)
  - Works well in young. Lack of data for older people.
  - Prevents severe disease
  - Easy to store (requires ultra cold refrigeration)
  - Efficacy variable, but ~80%
- **Novavax (51M doses)**
  - Recombinant protein; 2 doses;
  - Easy to store (requires ultra cold refrigeration)
  - Prevents severe disease
  - ~90% efficacy

## ***GOOD NEWS***

- All the vaccines are safe
- All significantly reduce serious disease and hospitalization
- No subgroups identified where they are ineffective
- Some evidence they reduce transmission
- Enough doses available to vaccinate whole population
- All can be adapted to work against variant viruses



## Caveats to all COVID-19 vaccines

- We do not know how long they provide protection (at least 3 mo).
- We know very little about their effect on asymptomatic disease (probably help)
- We don't know how well they prevent disease transmission. (probably reduce)
- Some are difficult to store and distribute.
- Many individual subgroups are yet to be specifically tested (children, pregnant women, aged)
- Their effectiveness may be lower against some mutant variants. Updates may be required.

# Virus variants (mutant viruses)

- **Viruses always mutate – it is not surprising that several have emerged**
- The concerning ones have mutations affecting the spike protein
- Vaccines target the spike protein, so changes can affect vaccine effectiveness.
- Vaccine efficacy seems lower against several variants.
- Some appear to be more transmissible (more infectious).
- Some (controversial) appear to be more dangerous.
- Variants will continue to appear – most have no effect, some may make the virus more transmissible; others may make it weaker.

# Summing up

- COVID-19 continues to spread and further outbreaks are likely in Australia.
- Vaccines will offer a lot of protection, especially against serious disease.
- Virus variants remain an ongoing threat.
- Vaccines will not immediately end the pandemic.
- Masks, social distancing and monitoring for outbreaks will be around for a while.
- “Be alert, but not alarmed”.

# Thanks and questions?